A5084791637- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Neutropenia and Cancer Infections
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Hematological disorders and diagnostics
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma Research and Treatments
- Childhood Cancer Survivors' Quality of Life
- Histone Deacetylase Inhibitors Research
- Chronic Lymphocytic Leukemia Research
- Retinoids in leukemia and cellular processes
- Phagocytosis and Immune Regulation
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- CAR-T cell therapy research
- Pancreatitis Pathology and Treatment
- Biomedical Ethics and Regulation
- Hemoglobinopathies and Related Disorders
- Protein Degradation and Inhibitors
- Complement system in diseases
- Mycobacterium research and diagnosis
- Immunotherapy and Immune Responses
- Cancer Treatment and Pharmacology
University of Washington
2016-2025
Griffith University
2025
Gold Coast Hospital
2011-2025
Fred Hutch Cancer Center
2016-2024
University of Washington Medical Center
2023
Seattle University
2017-2022
Seattle Cancer Care Alliance
2018-2021
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
2021
Centro de Investigación del Cáncer
2021
Cancer Research Center
2021
The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or yielded new information regarding factors prognostic importance, are intended aid physicians decision-making. These Insights focus recent select updates Guidelines, including familial genetic alterations AML, postinduction postremission strategies low-risk acute promyelocytic leukemia...
Abstract Purpose: TTI-621 (SIRPα-IgG1 Fc) is a novel checkpoint inhibitor that activates antitumor activity by blocking the CD47 “don't eat me” signal. This first-in-human phase I study (NCT02663518) evaluated safety and of in relapsed/refractory (R/R) hematologic malignancies. Patients Methods: with R/R lymphoma received escalating weekly intravenous to determine maximum tolerated dose (MTD). During expansion, patients various malignancies single-agent at MTD; was combined rituximab B-cell...
BACKGROUND Acute myeloid leukemia (AML) is treated with conventional induction chemotherapy shortly after diagnosis for the majority of patients aged ≤65 years. A recent report suggested a substantial decline in early, or 1‐month, mortality rate on clinical trials over past 2 decades. It unknown whether similar improvement has been observed general population. METHODS The authors examined 1‐month large population‐based series 9380 AML who were years and diagnosed between 1973 2010. RESULTS...
With increasing therapeutic alternatives available, there is growing interest in tools that accurately identify patients most suitable for intensive acute myeloid leukemia (AML) chemotherapy. Nowadays, conceptual criteria proposed by an Italian panel of experts are widely used this purpose. How these Ferrara predict fitness chemotherapy unknown.We assessed the adults undergoing AML therapy based on and determined accuracy assessment early mortality survival prediction.Among 655 who received...
This study explored community pharmacists' experiences and perceptions of information transfer from Queensland health hospitals for patients during transitions care the current utilization electronic medical records accessing patient information. Qualitative methodology was used involving in-depth semi-structured interviews with pharmacists to explore their patients' care. Purposive sampling ensure participation who had experience medication management discharged hospitals. Interviews were...
Secondary acute myeloid leukemia (sAML) is biologically and clinically distinct from de novo AML shares specific genetic mutations with myelodysplastic syndromes (MDS). We retrospectively analyzed data 295 adults MDS or mutational analysis by next-generation sequencing (NGS), examined differences in functional grouping of relation between morphologic blast count variant allele frequency (VAF) mutations. Our showed the distribution differed AML. However, these largely disappeared when we...
Options for adults with relapsed or refractory B-cell acute lymphoblastic leukemia lymphoma (B-ALL) are limited, and new approaches needed. Inotuzumab ozogamicin (InO) has been combined low-intensity chemotherapy, modest improvements over historical controls, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (DA-EPOCH) treatment is safe active newly diagnosed ALL.
In January 2020, the first documented patient in United States infected with severe acute respiratory syndrome coronavirus 2 was diagnosed Washington State. Since that time, community spread of disease 2019 (COVID-19) state has changed practice oncologic care at our comprehensive cancer center Seattle. At Seattle Cancer Care Alliance, primary oncology clinic for University Washington/Fred Hutchinson Consortium, specialists who manage adult patients hematologic malignancies have rapidly...
Abstract To improve patient quality of life and reduce health care costs, many conditions formerly thought to require inpatient are now treated in the outpatient setting. Outpatient induction chemotherapy for acute myeloid leukemia (AML) may confer similar benefits. This possibility prompted a pilot study explore safety feasibility intensive initial or salvage administration adults with AML high-risk myelodysplastic syndrome (MDS). Patients no significant organ dysfunction treatment-related...
Acute myeloid leukemia (AML) has an aggressive course and a historically dismal prognosis. For many patients, hematopoietic stem cell transplantation (HSCT) represents the best option for cure, but access, utilization, health inequities on global scale remain poorly elucidated. We wanted to describe patterns of HSCT use in AML better understanding practices, unmet needs internationally. Estimates incident cases 2016 were obtained from Global Burden Disease 2019 study. activities collected...
Abstract The presence of measurable residual disease (MRD) in acute lymphoblastic leukemia (ALL) confers a poor prognosis. CD19-targeted immunotherapy is effective against MRD but logistically challenging, potentially toxic, and not applicable to T-cell ALL. We thus hypothesized that inhibition PD-1 with pembrolizumab could also be for MRD, without lineage restriction. primary objective this phase 2 study was evaluate the efficacy patients ALL MRD. Key eligibility criteria included adults B-...
The outcome of sequential azacitidine with lenalidomide has not been reported in previously treated patients acute myeloid leukemia (AML) and higher risk myelodysplastic syndrome (MDS). This study describes a phase 2 evaluating the safety efficacy this combination elderly AML MDS prior hypomethylating agent (HMA) and/or immunomodulatory exposure. Patients were on 42-day cycle at 75 mg/m2 SQ/IV daily days 1-7, followed by 50 mg orally 8-28. median number treatment cycles was two (range =...
Treatments for adults with newly-diagnosed acute lymphoblastic leukemia (ALL) may be prohibitively toxic and/or resource-intense. To address this, we performed a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH). Imatinib or dasatinib was added Ph + disease; rituximab when CD20+. Fifty-three patients were evaluable: 28 disease, 25 Ph−. All had ≥1 high-risk clinical feature. Measurable residual disease-negativity by multiparameter...